Lima Urban Minority Alcohol Drug Abuse Outreach Program

Lima Urban Minority Alcohol Drug Abuse Outreach Program is a SAMHSA-registered addiction-treatment facility located at New York, NY. The facility's programming is outpatient (Outpatient, MAT), not residential. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at Lima Urban Minority Alcohol Drug Abuse Outreach Program

Level-of-care documentation: Lima Urban Minority Alcohol Drug Abuse Outreach Program is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Under MHPAEA 2024 medical-necessity criteria disclosure, plan-specific criteria for each of these levels must be available to patients upon request. Mismatch between documented clinical need and offered level of care is a common source of authorization denial.

Insurance and payment

Lima Urban Minority Alcohol Drug Abuse Outreach Program accepts Medicaid — which is consequential because facilities that accept Medicaid tend to have the broadest patient populations and the most developed public-sector relationships, though reimbursement structures mean program intensity sometimes differs from commercial-focused centers. The operational prerequisite for admission is written documentation of: (a) network contract status; (b) prior authorization; (c) cost-sharing structure; (d) medical-necessity criteria applied. Absence of any of these four increases the probability of post-admission financial disagreement.

Before you call

Pre-admission due-diligence for Lima Urban Minority Alcohol Drug Abuse Outreach Program: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via NY behavioral-health regulator inspection records. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.